Targeting MAPK in Cancer 2.0

Elisabetta Rovida; Ignazia Tusa

doi:10.3390/ijms23105702

Targeting MAPK in Cancer 2.0

Int J Mol Sci. 2022 May 20;23(10):5702. doi: 10.3390/ijms23105702.

Authors

Elisabetta Rovida¹, Ignazia Tusa¹

Affiliation

¹ Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.

Abstract

Mitogen-activated protein kinase (MAPK) pathways are prominently involved in the onset and progression of cancer [...].

Publication types

Editorial

MeSH terms

Humans
Mitogen-Activated Protein Kinases* / metabolism
Neoplasms* / drug therapy
Neoplasms* / genetics

Substances

Mitogen-Activated Protein Kinases

Grants and funding

Research carried out in E.R.’s lab is supported by the Associazione Italiana per la Ricerca sul Cancro, AIRC/FIRC, (IG), Ente Fondazione Cassa di Risparmio di Firenze (ECRF), and Università degli Studi di Firenze.